[go: up one dir, main page]

NO20064232L - Alfa.emitterende hydroksyapatittparikler - Google Patents

Alfa.emitterende hydroksyapatittparikler

Info

Publication number
NO20064232L
NO20064232L NO20064232A NO20064232A NO20064232L NO 20064232 L NO20064232 L NO 20064232L NO 20064232 A NO20064232 A NO 20064232A NO 20064232 A NO20064232 A NO 20064232A NO 20064232 L NO20064232 L NO 20064232L
Authority
NO
Norway
Prior art keywords
hydroxyapatite particles
alpha
alpha emitting
emitting hydroxyapatite
emitting radionuclide
Prior art date
Application number
NO20064232A
Other languages
English (en)
Inventor
Gro Salberg
Roy Larsen
Original Assignee
Algeta As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2005/000616 external-priority patent/WO2005079867A2/en
Application filed by Algeta As filed Critical Algeta As
Publication of NO20064232L publication Critical patent/NO20064232L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Confectionery (AREA)

Abstract

Den foreliggende oppfinnelsen tilveiebringer hydroksyapatitt (HA) inkorporerende en alfaemitterende radionukhde eller en in vivo generator for en alfaemitterende radionuklide. Oppfinnelsen tilveiebringer videre metoder for fremstilling av slik HA, farmasøytiske sammensetninger omfattende HA'en og metoder for medisinsk behandling av cancerøs eller ikke-cancerøs sykdom inkludert administrering av HA'en eller sammensetninger derav.
NO20064232A 2004-02-20 2006-09-19 Alfa.emitterende hydroksyapatittparikler NO20064232L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0403856.8A GB0403856D0 (en) 2004-02-20 2004-02-20 Composition
PCT/GB2005/000616 WO2005079867A2 (en) 2004-02-20 2005-02-18 Alpha-emitting hydroxyapatite particles

Publications (1)

Publication Number Publication Date
NO20064232L true NO20064232L (no) 2006-09-19

Family

ID=32040119

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064232A NO20064232L (no) 2004-02-20 2006-09-19 Alfa.emitterende hydroksyapatittparikler

Country Status (13)

Country Link
JP (1) JP5214884B2 (no)
KR (2) KR20070038030A (no)
CN (1) CN1972720B (no)
AT (1) ATE544492T1 (no)
DK (1) DK1735013T3 (no)
ES (1) ES2382041T3 (no)
GB (1) GB0403856D0 (no)
IL (1) IL177354A (no)
NO (1) NO20064232L (no)
NZ (1) NZ549080A (no)
PT (1) PT1735013E (no)
TW (1) TWI347194B (no)
ZA (1) ZA200606728B (no)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3111959T1 (en) * 2015-07-03 2018-04-30 Oncoinvent As Radiotherapeutic particles and suspensions
US20170065731A1 (en) * 2015-09-06 2017-03-09 Medical Theranostics Inc. Method, Apparatus, and System for Radiation Therapy
CN106344927A (zh) * 2016-09-27 2017-01-25 大连理工大学 叶酸修饰的载药羟基磷灰石及其制备方法
CA3192423A1 (en) * 2020-09-15 2022-03-24 Roy H. Larsen Size controlled radiolabelled particles
WO2024146921A1 (en) * 2023-01-05 2024-07-11 Oncoinvent As Alpha-emitting radionuclides for use in the treatment of peritoneal cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2097927A1 (en) * 1990-12-21 1992-06-22 Edward A. Deutsch Radionuclide labelled particles useful for radiation synovectomy
JP4194113B2 (ja) * 1993-10-26 2008-12-10 トーマス・ジェファーソン・ユニバーシティ 結腸直腸癌細胞に特異的に結合する組成物およびその使用方法
WO1997001304A1 (en) * 1995-06-29 1997-01-16 Mallinckrodt Medical, Inc. Radiolabeled apatite particles containing a paramagnetic ion
CN1287859C (zh) * 1999-10-18 2006-12-06 费克斯公司 定向递送生物活性剂的由铁和多孔材料构成的磁引导载体
JP3836444B2 (ja) * 2002-05-30 2006-10-25 独立行政法人科学技術振興機構 ハイドロキシアパタイト複合体およびその製造方法、ならびに、それを用いた医療用材料

Also Published As

Publication number Publication date
ATE544492T1 (de) 2012-02-15
ES2382041T3 (es) 2012-06-04
PT1735013E (pt) 2012-05-08
GB0403856D0 (en) 2004-03-24
CN1972720B (zh) 2010-07-07
NZ549080A (en) 2011-01-28
TWI347194B (en) 2011-08-21
KR20100060029A (ko) 2010-06-04
KR20070038030A (ko) 2007-04-09
JP5214884B2 (ja) 2013-06-19
JP2007528373A (ja) 2007-10-11
ZA200606728B (en) 2007-12-27
CN1972720A (zh) 2007-05-30
IL177354A0 (en) 2006-12-10
DK1735013T3 (da) 2012-05-21
TW200536558A (en) 2005-11-16
KR101165518B1 (ko) 2012-07-16
IL177354A (en) 2013-04-30

Similar Documents

Publication Publication Date Title
EA200601524A1 (ru) Альфа-излучающие частицы гидроксиапатита
MX383644B (es) Combinaciones y metodos de administracion de agentes terapeuticos y terapia de combinacion.
SI1472541T1 (sl) Prikazovalni agensi in postopek prikazovanja naaladase ali psma
LTPA2017009I1 (lt) Brutono tirozinkinazės inhibitoriai
NO20003457L (no) Bensökende alfapartikkel emitterende radiofarmasöytika
CY1112387T1 (el) Θεραπευτικη συνθεση περιεχουσα τουλαχιστον ενα παραγωγο της πυρρολοβενζοδιαζεπινης και φλουδαραβινη
CY1112055T1 (el) Συνθεσεις και μεθοδοι για την διαγνωση και θεραπευτικη αγωγη ογκου πνευμονα
IL176007A0 (en) Antibodies specific to c35 and pharmaceutical compositions containing the same
BRPI0508700A (pt) uso de sns-595, composição farmacêutica, e, pó liofilizado
IL189104A (en) Pharmaceutical preparation containing lasalazide or sodium balasalazide for use in the treatment of gastrointestinal disorders.
TW200509863A (en) Irradiation device for medical use
NO20064232L (no) Alfa.emitterende hydroksyapatittparikler
ATE480552T1 (de) Stq-peptide
ATE382347T1 (de) Pharmazeutische zusammensetzung zur verwendung bei der behandlung von malignen erkrankungen, umfassend eine kombination aus bisphosphonaten, einem cox-2 inhibitor und einem taxol
WO2003076651A3 (en) Cancer associated araf1 protein kinase and its uses
EA200600987A1 (ru) Применение сирамезина в лечении злокачественных опухолей

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application